ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC was delisted on the 16th of October, 2018.
16 hedge funds and large institutions have $221K invested in ImmunoCellular Therapeutics, Ltd. in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
6% less funds holding
Funds holding: 17 → 16 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
79% less capital invested
Capital invested by funds: $1.04M → $221K (-$818K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
+$61.3K |
| 2 |
Renaissance Technologies
New York
|
+$24.2K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$23.2K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.6K |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$8 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$445K |
| 2 |
IP
Intellectus Partners
San Francisco,
California
|
-$9K |
| 3 |
Morgan Stanley
New York
|
-$101 |
IMUC Hedge Fund Activity: Q2 2017 in Review
16 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q2 2017, worth a combined $221K — down 79% from $1.04M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of IMUC and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.
The largest buyer was Wedbush Securities, opening a new position worth an estimated $61.3K. The largest seller was Sabby Management, exiting entirely with an estimated $445K sold.
- 16 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q2 2017, down from 17 in Q1 2017.
- Funds reported $221K of ImmunoCellular Therapeutics, Ltd. stock for Q2 2017, down 79% quarter-over-quarter.
- 2 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q2 2017 and 3 closed out, a net change of -1 holder.
- The largest ImmunoCellular Therapeutics, Ltd. buyer in Q2 2017 was Wedbush Securities, an estimated $61.3K added.
- The largest ImmunoCellular Therapeutics, Ltd. seller in Q2 2017 was Sabby Management, an estimated $445K sold.
Based on aggregated 13F filings for Q2 2017.